SCHEMBL5245484

SCHEMBL5245484

Cc1cccc(N2CCN(S(=O)(=O)c3ccc(Cl)c4nonc34)CC2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 4/20 0.48
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
F13A1 P00488 1/20 0.45
TGM2 P21980 1/20 0.45
TGM1 P22735 1/20 0.45
TGM3 Q08188 1/20 0.45
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
GAA P10253 2/20 0.45
LMNA P02545 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5242980 0.85 KMT2A (0.53) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5242949 0.80 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5243664 0.79 ALDH1A1 (0.61) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5286887 0.78 POLB (0.56) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5245000 0.78 SMN1; SMN2 (0.52) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL8160562 0.77 HSD11B1 (0.57) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL5371333 0.74 MEN1 (0.54) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL18711645 0.74 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL5286862 0.73 LMNA (0.43) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL18701910 0.72 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP ALDH1A1 2627/4885KMT2A 1303/4885MEN1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.